A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Conditions
Waldenstrom Macroglobulinemia · Lymphoplasmacytic Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Dana Farber Cancer Institute (Data Collection and Specimen Analysis), Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center (Data Collection Only), Boston, Massachusetts, United States
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk - Commack, Commack, New York, United States
Memorial Sloan Kettering Westchester, Harrison, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
Study leads
M. Lia Palomba, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center